Seropositive rheumatoid arthritis after vaccination against SARS‐CoV‐2 infection

Abstract

Dear Editor, Today a frequently asked question is: Can vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trigger rheumatic and musculoskeletal diseases? Several cases of arthritis have been reported after vaccination against SARS-CoV-2. 1-4 A few articles have investigated the safety of SPUTNIK-V; 5 there is only our one case of arthritis reported after this vaccination. 1 In our International Journal of Rheumatic Diseases paper about arthritis after vaccination against SARS-CoV-2 1 we wrote: 'Several patients with rheumatic diseases, treated in the Medical Center of Joint Diseases (MCJD), developed transient flares after receiving the COVID-19 vaccine'. A possible association between rheumatoid arthritis (RA) and influenza vaccination was previously reported in a cohort study; 6 however, there were no cases of seropositive RA after SPUTNIK-V vaccination in the literature. A heterologous recombinant adenovirus-based vaccine, Gam-COVID-Vac (Sputnik V, Gamaleya National Research Centre for Epidemiology and Microbiology), showed a good safety profile and induced strong humoral and cellular immune responses. 5 We would like to present the first case of new-onset seropositive (for rheumatoid factor [RF] and anti-citrullinated protein antibodies [ACPA]) RA after a single dose of SPUTNIK-V vaccine. We report the case of a 38-year-old Asian non-smoking woman with no history of chronic joint disease, infections, injuries, inflammatory back pain, morning stiffness, or joint swelling. The patient had no previous symptoms of SARS-CoV-2 infection; a serological anti-SARS-CoV-2 rapid test (COVID-19 IgG/IgM antibody test; Humasis,Germany) was negative. The patient received the first dose of the SPUTNIK-V vaccine on May 20, 2021 without developing a fever or adverse events. Twenty days later, | 1441 CORRESPONDENCE RA, though controlled studies are needed to prove this hypothesis.

Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study

“…Prioritized vaccination of patients with autoimmune and inflammatory RMDs to reduce COVID-19 risk was proposed by the American College of Rheumatology (ACR) ( 12 ), and a considerable amount of data on the efficacy and safety of mRNA-based vaccination in immunosuppressed patients is available ( 11 ). However, data on adenovirus-based and inactivated SARS-CoV-2 vaccines in patients with autoimmune and inflammatory RMDs are limited ( 13 , 14 ).…”

Rheumatoid arthritis and post-COVID-19 syndrome

“…Это соответствует данным о возможной триггерной роли респираторных и других вирусов в развитии этой патологии [28][29][30]. Мы также предполагаем, что инфекция SARS-CoV-2 (или вакцинация против SARS-CoV-2) может быть триггерным фактором поражения суставов, в том числе вызывать обострение РА или индуцировать развитие РА [31][32][33][34][35][36][37][38][39][40][41]. Мы наблюдали пациента, у которого незадолго до заболевания COVID-19 увеличение титров АЦЦП и РФ отмечено не было [32], не наблюдалось характерного для РА поражения мелких суставов кисти.…”

Flare of adult-onset Still’s disease following mRNA COVID-19 vaccination: a case report and review of literature

“…Theoretically, an innovative vaccine of COVID-19 may behave like an adjuvant, resulting in perturbations in immune system, acting as a potential trigger for AOSD. As of concern, several cases of flares of other AIAIDs [ 9 , 35 ] or new diagnoses of AOSD due to COVID-19 vaccination have been reported [ 12 – 16 ]. On the other hand, to the best of our knowledge, there have been only two cases of flare up of AOSD reported following COVID-19 vaccination [ 10 , 11 ].…”